Résultats de recherche - Portail des modèles médicaux de données (portail MDM)

Filtrer les résultats de recherche
Sélectionner modèles de données

Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

22 Résultats de recherche.

Eligibility Mantle Cell Lymphoma NCT01439750

- 20/09/2021 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011); ODM derived from: https://clinicaltrials.gov/show/NCT01439750

Eligibility Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma NCT01693614

- 01/12/2019 - 1 Formulaire, 2 Groupes Item, 15 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Safety and Efficacy of BKM120 in Relapsed and Refractory NHL; ODM derived from: https://clinicaltrials.gov/show/NCT01693614

Eligibility Lymphoma, Mantle-Cell NCT02413489

- 02/05/2019 - 1 Formulaire, 2 Groupes Item, 10 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT02413489

Eligibility Lymphoma, Mantle-Cell NCT02419560

- 30/04/2019 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Optimal Dose Finding Study ABT-199 and Ibrutinib in MCL; ODM derived from: https://clinicaltrials.gov/show/NCT02419560

Eligibility Non-Hodgkin's Lymphoma (NHL) NCT01180049

- 08/01/2019 - 1 Formulaire, 2 Groupes Item, 9 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Comparison Of 2 Doses Of Temsirolimus (Torisel) In Patients With Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT01180049

Eligibility Mantle Cell Lymphoma NCT00963534

- 14/06/2018 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Lenalidomide, Bendamustine and Rituximab as First-line Therapy for Patients Over 65 Years With Mantle Cell Lymphoma.; ODM derived from: https://clinicaltrials.gov/show/NCT00963534

Eligibility Mantle Cell Lymphoma NCT00737529

- 14/06/2018 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial; ODM derived from: https://clinicaltrials.gov/show/NCT00737529

Eligibility Mantle Cell Lymphoma NCT00541424

- 14/06/2018 - 1 Formulaire, 2 Groupes Item, 16 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Combined CT Colonography and PET Imaging in Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00541424

Eligibility Lymphoma, Mantle-Cell NCT00871546

- 04/06/2018 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715); ODM derived from: https://clinicaltrials.gov/show/NCT00871546

Eligibility Contiguous Stage II Mantle Cell Lymphoma NCT00433537

- 11/01/2018 - 1 Formulaire, 2 Groupes Item, 19 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00433537

Eligibility Non-Hodgkin's Lymphoma NCT00612183

- 02/06/2017 - 1 Formulaire, 2 Groupes Item, 18 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Clinical Study on SyB L-0501 in Patients With Indolent B-cell Non-Hodgkin's Lymphoma or Mantle Cell Lymphoma; ODM derived from: https://clinicaltrials.gov/show/NCT00612183

Eligibility Mantle Cell Lymphoma NCT00505232

- 03/05/2017 - 1 Formulaire, 2 Groupes Item, 17 Eléments de données, 1 Langue

Groupes Item: Inclusion Criteria, Exclusion Criteria

Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02); ODM derived from: https://clinicaltrials.gov/show/NCT00505232

Utilisez ce formulaire pour les retours, les questions et les améliorations suggérées.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.